BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers 2015;1:15010. [PMID: 27189798 DOI: 10.1038/nrdp.2015.10] [Cited by in Crossref: 218] [Cited by in F6Publishing: 191] [Article Influence: 31.1] [Reference Citation Analysis]
Number Citing Articles
1 Kerem E, Cohen-Cymberknoh M, Tsabari R, Wilschanski M, Reiter J, Shoseyov D, Gileles-Hillel A, Pugatsch T, Davies JC, Short C, Saunders C, DeSouza C, Sullivan JC, Doyle JR, Chandarana K, Kinnman N. Ivacaftor in People with Cystic Fibrosis and a 3849+10kb CT or D1152H Residual Function Mutation. Ann Am Thorac Soc 2021;18:433-41. [PMID: 33095038 DOI: 10.1513/AnnalsATS.202006-659OC] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
2 Kwong K, Benedetti A, Yau Y, Waters V, Nguyen D. Failed eradication therapy of new onset Pseudomonas aeruginosa infections in cystic fibrosis children is associated with bacterial resistance to neutrophil functions. J Infect Dis 2021:jiab102. [PMID: 33606875 DOI: 10.1093/infdis/jiab102] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel P, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-hamblett N, Kashirskaya N, Kerem E, Mathew JL, Mckone EF, Naehrlich L, Nasr SZ, Oates GR, O'neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. The Lancet Respiratory Medicine 2020;8:65-124. [DOI: 10.1016/s2213-2600(19)30337-6] [Cited by in Crossref: 183] [Cited by in F6Publishing: 82] [Article Influence: 91.5] [Reference Citation Analysis]
4 Ellis S, Rang C, Kotsimbos T, Keating D, Finlayson F, Stark R, Thyagarajan D, Wilson J. CNS imaging studies in cystic fibrosis patients presenting with sudden neurological events. BMJ Open Respir Res 2019;6:e000456. [PMID: 31423315 DOI: 10.1136/bmjresp-2019-000456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Wang Y, Tang N. The diversity of adult lung epithelial stem cells and their niche in homeostasis and regeneration. Sci China Life Sci 2021. [PMID: 33948870 DOI: 10.1007/s11427-020-1902-3] [Reference Citation Analysis]
6 Mejías JC, Roy K. In-vitro and in-vivo characterization of a multi-stage enzyme-responsive nanoparticle-in-microgel pulmonary drug delivery system. J Control Release 2019;316:393-403. [PMID: 31715279 DOI: 10.1016/j.jconrel.2019.09.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ruksakiet K, Stercz B, Tóth G, Jaikumpun P, Gróf I, Tengölics R, Lohinai ZM, Horváth P, Deli MA, Steward MC, Dobay O, Zsembery Á. Bicarbonate Evokes Reciprocal Changes in Intracellular Cyclic di-GMP and Cyclic AMP Levels in Pseudomonas aeruginosa. Biology (Basel) 2021;10:519. [PMID: 34200909 DOI: 10.3390/biology10060519] [Reference Citation Analysis]
8 Allan KM, Farrow N, Donnelley M, Jaffe A, Waters SA. Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies. Front Pharmacol 2021;12:639475. [PMID: 33796025 DOI: 10.3389/fphar.2021.639475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Vazirani J, Crowhurst T, Morrissey CO, Snell GI. Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis. Infect Drug Resist 2021;14:5293-301. [PMID: 34916813 DOI: 10.2147/IDR.S301153] [Reference Citation Analysis]
10 Beaufils F, Mas E, Mittaine M, Addra M, Fayon M, Delhaes L, Clouzeau H, Galode F, Lamireau T, Bui S, Enaud R. Increased Fecal Calprotectin Is Associated with Worse Gastrointestinal Symptoms and Quality of Life Scores in Children with Cystic Fibrosis. J Clin Med 2020;9:E4080. [PMID: 33348735 DOI: 10.3390/jcm9124080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Stanford G, Ryan H, Solis-Moya A. Respiratory muscle training for cystic fibrosis. Cochrane Database Syst Rev 2020;12:CD006112. [PMID: 33331663 DOI: 10.1002/14651858.CD006112.pub5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Coton J, Le HH, Veuillet V, Janiaud P, Cucherat M, Kassai-Koupai B, Gueyffier F, Reix P. Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response? A meta-analysis. J Cyst Fibros 2019;18:461-7. [PMID: 30772244 DOI: 10.1016/j.jcf.2019.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Ratjen F, Davis SD, Stanojevic S, Kronmal RA, Hinckley Stukovsky KD, Jorgensen N, Rosenfeld M, Kerby G, Kopecky C, Anthony M, Mogayzel P, Walker D, Zeglin B, Hoover W, Hathorne H, Slaten K, Dorkin H(, Fowler R, Fenton C(, Ulles M, Goetz D, Caci N, Cahill B, Roach C, Retsch-bogart G, Johnson R, Cunnion R, Mccolley S, Ward S, Bell E, Mcphail G, Keller K, Thornton K, Parsons A, Chmiel J, Schaefer C, Tribout M, Consiglio B, Tribout H, Mccoy K, Johnson T, Olson P, Raterman L, Hiatt P, Walker B, Schaap N, Davis M, Davis S, Clem C, Bendy L, Starner T, Lux C, Carver T, Thompson R, Williams A, Schmoll C, Hastings PM, Noe J, Roth L, Kump T, Mcnamara J, Franck Thompson E, Yousef S, Wezel G(, Oquendo O, Darling A, Valencia W, Milla C, Zirbes J, Rubenstein R, Donnelly E, Malpass J, Weiner D, Agostini B, Hartigan E, Cornell A, Klein B, Bucher J, Nusbaum P, Rosenfeld M, Mcnamara S, Genatossio A, Pittman J, Hicks T, Bauer I, Siegel M, Isaac S, Jensen R, Au J, Stanojevic S, Ratjen F, Mcdonald N, Prentice C, Chilvers M, Richmond M. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine 2019;7:802-9. [DOI: 10.1016/s2213-2600(19)30187-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 12.3] [Reference Citation Analysis]
14 Kaber G, Kratochvil MJ, Burgener EB, Peltan EL, Barlow G, Yang S, Nicolls MR, de Jesus Perez V, Rosser JI, Wardle AJ, Kalinowski A, Ozawa MG, Regula DP, Nagy N, Heilshorn SC, Milla CE, Rogers AJ, Bollyky PL. Hyaluronan is abundant in COVID-19 respiratory secretions. medRxiv 2020:2020. [PMID: 32935110 DOI: 10.1101/2020.09.11.20191692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
15 Chin M, Aaron SD, Bell SC. The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Med 2017;46:e139-64. [PMID: 28576636 DOI: 10.1016/j.lpm.2016.11.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Izydorczyk C, Waddell B, Edwards BD, Greysson-Wong J, Surette MG, Somayaji R, Rabin HR, Conly JM, Church DL, Parkins MD. Epidemiology of E. coli in Cystic Fibrosis Airways Demonstrates the Capacity for Persistent Infection but Not Patient-Patient Transmission. Front Microbiol 2020;11:475. [PMID: 32265892 DOI: 10.3389/fmicb.2020.00475] [Reference Citation Analysis]
17 Collin AM, Lecocq M, Detry B, Carlier FM, Bouzin C, de Sany P, Hoton D, Verleden S, Froidure A, Pilette C, Gohy S. Loss of ciliated cells and altered airway epithelial integrity in cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)01424-7. [PMID: 34657818 DOI: 10.1016/j.jcf.2021.09.019] [Reference Citation Analysis]
18 Bose SJ, Bijvelds MJC, Wang Y, Liu J, Cai Z, Bot AGM, de Jonge HR, Sheppard DN. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR. Am J Physiol Lung Cell Mol Physiol 2019;317:L71-86. [PMID: 30969810 DOI: 10.1152/ajplung.00034.2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
19 Rodrat M, Jantarajit W, Ng DRS, Harvey BSJ, Liu J, Wilkinson WJ, Charoenphandhu N, Sheppard DN. Carbon monoxide-releasing molecules inhibit the cystic fibrosis transmembrane conductance regulator Cl- channel. Am J Physiol Lung Cell Mol Physiol 2020;319:L997-L1009. [PMID: 32936026 DOI: 10.1152/ajplung.00440.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respir Med 2021:S2213-2600(21)00069-2. [PMID: 33965000 DOI: 10.1016/S2213-2600(21)00069-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Guerra L, Favia M, Di Gioia S, Laselva O, Bisogno A, Casavola V, Colombo C, Conese M. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Expert Opin Drug Discov 2020;15:873-91. [PMID: 32290721 DOI: 10.1080/17460441.2020.1750592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
22 Minkiewicz-Zochniak A, Strom K, Jarzynka S, Iwańczyk B, Koryszewska-Bagińska A, Olędzka G. Effect of Low Amperage Electric Current on Staphylococcus Aureus-Strategy for Combating Bacterial Biofilms Formation on Dental Implants in Cystic Fibrosis Patients, In Vitro Study. Materials (Basel) 2021;14:6117. [PMID: 34683710 DOI: 10.3390/ma14206117] [Reference Citation Analysis]
23 Shi X, Gao Z, Lin Q, Zhao L, Ma Q, Kang Y, Yu J. Meta-analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients. Genomics Proteomics Bioinformatics 2019;17:590-602. [PMID: 32171662 DOI: 10.1016/j.gpb.2018.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Francis F, Enaud R, Soret P, Lussac-Sorton F, Avalos-Fernandez M, MucoFong Investigation Group, Bui S, Fayon M, Thiébaut R, Delhaes L. New Insights in Microbial Species Predicting Lung Function Decline in CF: Lessons from the MucoFong Project. J Clin Med 2021;10:3725. [PMID: 34442021 DOI: 10.3390/jcm10163725] [Reference Citation Analysis]
25 Meeker SM, Mears KS, Sangwan N, Brittnacher MJ, Weiss EJ, Treuting PM, Tolley N, Pope CE, Hager KR, Vo AT, Paik J, Frevert CW, Hayden HS, Hoffman LR, Miller SI, Hajjar AM. CFTR dysregulation drives active selection of the gut microbiome. PLoS Pathog 2020;16:e1008251. [PMID: 31961914 DOI: 10.1371/journal.ppat.1008251] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
26 Zepp JA, Morrisey EE. Cellular crosstalk in the development and regeneration of the respiratory system. Nat Rev Mol Cell Biol 2019;20:551-66. [PMID: 31217577 DOI: 10.1038/s41580-019-0141-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 16.7] [Reference Citation Analysis]
27 Konishi CT, Long C. Progress and challenges in CRISPR-mediated therapeutic genome editing for monogenic diseases. J Biomed Res 2020;35:148-62. [PMID: 33402545 DOI: 10.7555/JBR.34.20200105] [Reference Citation Analysis]
28 Zhang J, Wang Y, Jiang X, Chan HC. Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer. Cell Mol Life Sci. 2018;75:1737-1756. [PMID: 29411041 DOI: 10.1007/s00018-018-2755-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
29 Hutt DM, Loguercio S, Roth DM, Su AI, Balch WE. Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation. J Biol Chem 2018;293:13477-95. [PMID: 30006345 DOI: 10.1074/jbc.RA118.003192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
30 Noel S, Servel N, Hatton A, Golec A, Rodrat M, Ng DRS, Li H, Pranke I, Hinzpeter A, Edelman A, Sheppard DN, Sermet-Gaudelus I. Correlating genotype with phenotype using CFTR-mediated whole-cell Cl- currents in human nasal epithelial cells. J Physiol 2021. [PMID: 34761808 DOI: 10.1113/JP282143] [Reference Citation Analysis]
31 Lascano-Vaca Y, Ortiz-Prado E, Gomez-Barreno L, Simbaña-Rivera K, Vasconez E, Lister A, Arteaga-Espinosa ME, Perez GF. Clinical, genetic and microbiological characterization of pediatric patients with cystic fibrosis in a public Hospital in Ecuador. BMC Pediatr 2020;20:111. [PMID: 32143663 DOI: 10.1186/s12887-020-2013-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Shei RJ, Dekerlegand RL, Mackintosh KA, Lowman JD, McNarry MA. Inspiration for the Future: The Role of Inspiratory Muscle Training in Cystic Fibrosis. Sports Med Open 2019;5:36. [PMID: 31396726 DOI: 10.1186/s40798-019-0210-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Renner S, Nachbaur E, Jaksch P, Dehlink E. Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation. J Fungi (Basel) 2020;6:381. [PMID: 33371198 DOI: 10.3390/jof6040381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Zhang X, Pan A, Jia S, Ideozu JE, Woods K, Murkowski K, Hessner MJ, Simpson PM, Levy H. Cystic Fibrosis Plasma Blunts the Immune Response to Bacterial Infection. Am J Respir Cell Mol Biol 2019;61:301-11. [PMID: 30848661 DOI: 10.1165/rcmb.2018-0114OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
35 Graziano S, Spanò B, Majo F, Righelli D, Vincenzina L, Quittner A, Tabarini P. Rates of depression and anxiety in Italian patients with cystic fibrosis and parent caregivers: Implementation of the Mental Health Guidelines. Respir Med 2020;172:106147. [PMID: 32961510 DOI: 10.1016/j.rmed.2020.106147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
37 Cho DY, Zhang S, Skinner DF, Lim DJ, Banks C, Grayson JW, Tearney GJ, Rowe SM, Woodworth BA. Ivacaftor restores delayed mucociliary transport caused by Pseudomonas aeruginosa-induced acquired cystic fibrosis transmembrane conductance regulator dysfunction in rabbit nasal epithelia. Int Forum Allergy Rhinol 2021. [PMID: 34704673 DOI: 10.1002/alr.22907] [Reference Citation Analysis]
38 Stanton BA, Hampton TH, Ashare A. SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2020;319:L408-15. [PMID: 32668165 DOI: 10.1152/ajplung.00225.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
39 Klockgether J, Cramer N, Fischer S, Wiehlmann L, Tümmler B. Long-Term Microevolution of Pseudomonas aeruginosa Differs between Mildly and Severely Affected Cystic Fibrosis Lungs. Am J Respir Cell Mol Biol 2018;59:246-56. [PMID: 29470920 DOI: 10.1165/rcmb.2017-0356OC] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
40 Dong K, Moon KM, Chen V, Ng R, Foster LJ, Tebbutt SJ, Quon BS. Identification of novel blood biomarkers of treatment response in cystic fibrosis pulmonary exacerbations by label-free quantitative proteomics. Sci Rep 2019;9:17126. [PMID: 31748618 DOI: 10.1038/s41598-019-53759-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
41 Almughem FA, Aldossary AM, Tawfik EA, Alomary MN, Alharbi WS, Alshahrani MY, Alshehri AA. Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies. Pharmaceutics 2020;12:E616. [PMID: 32630625 DOI: 10.3390/pharmaceutics12070616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Dongarwar D, Garcia BY, Miller K, Salihu HM. Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. J Natl Med Assoc 2021:S0027-9684(21)00190-5. [PMID: 34479733 DOI: 10.1016/j.jnma.2021.08.038] [Reference Citation Analysis]
43 Brinkert K, Hedtfeld S, Burhop A, Gastmeier R, Gad P, Wedekind D, Kloth C, Rothschuh J, Lachmann N, Hetzel M, Jirmo AC, Lopez-Rodriguez E, Brandenberger C, Hansen G, Schambach A, Ackermann M, Tümmler B, Munder A. Rescue from Pseudomonas aeruginosa Airway Infection via Stem Cell Transplantation. Mol Ther 2021;29:1324-34. [PMID: 33279724 DOI: 10.1016/j.ymthe.2020.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Masood A, Jacob M, Gu X, Abdel Jabar M, Benabdelkamel H, Nizami I, Li L, Dasouki M, Abdel Rahman AM. Distinctive metabolic profiles between Cystic Fibrosis mutational subclasses and lung function. Metabolomics 2021;17:4. [PMID: 33394183 DOI: 10.1007/s11306-020-01760-5] [Reference Citation Analysis]
45 Gale PA, Davis JT, Quesada R. Anion transport and supramolecular medicinal chemistry. Chem Soc Rev 2017;46:2497-519. [DOI: 10.1039/c7cs00159b] [Cited by in Crossref: 189] [Cited by in F6Publishing: 35] [Article Influence: 37.8] [Reference Citation Analysis]
46 Stanke F, Janciauskiene S, Tamm S, Wrenger S, Raddatz EL, Jonigk D, Braubach P. Effect of Alpha-1 Antitrypsin on CFTR Levels in Primary Human Airway Epithelial Cells Grown at the Air-Liquid-Interface. Molecules 2021;26:2639. [PMID: 33946490 DOI: 10.3390/molecules26092639] [Reference Citation Analysis]
47 Esposito S, Villella VR, Rossin F, Tosco A, Raia V, Luciani A. Succinate links mitochondria to deadly bacteria in cystic fibrosis. Ann Transl Med 2019;7:S263. [PMID: 32015982 DOI: 10.21037/atm.2019.12.49] [Reference Citation Analysis]
48 Wiehlmann L, Cramer N, Tümmler B. Habitat-associated skew of clone abundance in the Pseudomonas aeruginosa population. Environ Microbiol Rep 2015;7:955-60. [PMID: 26419222 DOI: 10.1111/1758-2229.12340] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
49 Sheikh Z, Bradbury P, Pozzoli M, Young PM, Ong HX, Traini D. An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. Eur J Pharm Biopharm 2020;156:121-30. [PMID: 32916267 DOI: 10.1016/j.ejpb.2020.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Bernstein R, Lynn C, Faro A, Barker D, Quittner A. Pretransplant Quality of Life and Post-Transplant Survival in Adolescents with Cystic Fibrosis. J Pediatr Psychol 2021:jsab105. [PMID: 34718670 DOI: 10.1093/jpepsy/jsab105] [Reference Citation Analysis]
51 Liu J, Bihler H, Farinha CM, Awatade NT, Romão AM, Mercadante D, Cheng Y, Musisi I, Jantarajit W, Wang Y, Cai Z, Amaral MD, Mense M, Sheppard DN. Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule. Br J Pharmacol 2018;175:1017-38. [PMID: 29318594 DOI: 10.1111/bph.14141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
52 Lauwers E, Belmans D, Mignot B, Ides K, Van Hoorenbeeck K, Snoeckx A, Van Holsbeke C, Nowé V, Van Braeckel E, De Backer W, De Backer J, Verhulst S. The short-term effects of ORKAMBI (lumacaftor/ivacaftor) on regional and distal lung structures using functional respiratory imaging. Ther Adv Respir Dis 2021;15:17534666211046774. [PMID: 34541955 DOI: 10.1177/17534666211046774] [Reference Citation Analysis]
53 Dediu M, Ciuca IM, Marc MS, Boeriu E, Pop LL. Factors Influencing Lung Function in Patients with Cystic Fibrosis in Western Romania. J Multidiscip Healthc 2021;14:1423-9. [PMID: 34163170 DOI: 10.2147/JMDH.S313209] [Reference Citation Analysis]
54 Lauwers E, Ides K, Van Hoorenbeeck K, Verhulst S. Outcome measures for airway clearance techniques in children with chronic obstructive lung diseases: a systematic review. Respir Res 2020;21:217. [PMID: 32807200 DOI: 10.1186/s12931-020-01484-z] [Reference Citation Analysis]
55 Michaels WE, Bridges RJ, Hastings ML. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells. Nucleic Acids Res 2020;48:7454-67. [PMID: 32520327 DOI: 10.1093/nar/gkaa490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
56 Lingam S, Thonghin N, Ford RC. Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1). Sci Rep 2017;7:17481. [PMID: 29235532 DOI: 10.1038/s41598-017-17773-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
57 Wilson J, You X, Ellis M, Urquhart DS, Jha L, Duncan M, Tian S, Harris RA, Kotsimbos T, Keating D. VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial. J Cyst Fibros 2021;20:499-505. [PMID: 33358691 DOI: 10.1016/j.jcf.2020.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ubago-Guisado E, Cavero-Redondo I, Alvarez-Bueno C, Vlachopoulos D, Martínez-Vizcaíno V, Gracia-Marco L. Bone Health in Children and Youth with Cystic Fibrosis: A Systematic Review and Meta-Analysis of Matched Cohort Studies. J Pediatr 2019;215:178-186.e16. [PMID: 31519442 DOI: 10.1016/j.jpeds.2019.07.073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Matthes E, Goepp J, Martini C, Shan J, Liao J, Thomas DY, Hanrahan JW. Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine. Front Pharmacol 2018;9:1490. [PMID: 30618775 DOI: 10.3389/fphar.2018.01490] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
60 Della Sala A, Prono G, Hirsch E, Ghigo A. Role of Protein Kinase A-Mediated Phosphorylation in CFTR Channel Activity Regulation. Front Physiol 2021;12:690247. [PMID: 34211404 DOI: 10.3389/fphys.2021.690247] [Reference Citation Analysis]
61 Awatade NT, Wong SL, Capraro A, Pandzic E, Slapetova I, Zhong L, Turgutoglu N, Fawcett LK, Whan RM, Jaffe A, Waters SA. Significant functional differences in differentiated Conditionally Reprogrammed (CRC)- and Feeder-free Dual SMAD inhibited-expanded human nasal epithelial cells. J Cyst Fibros 2021;20:364-71. [PMID: 33414087 DOI: 10.1016/j.jcf.2020.12.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Hutt DM, Mishra SK, Roth DM, Larsen MB, Angles F, Frizzell RA, Balch WE. Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy. J Biol Chem 2018;293:13682-95. [PMID: 29986884 DOI: 10.1074/jbc.RA118.002607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
63 Lam C, Santell L, Wilson B, Yim M, Louie S, Tang D, Shaw D, Chan P, Lazarus RA, Snedecor B, Misaghi S. Taming hyperactive hDNase I: Stable inducible expression of a hyperactive salt- and actin-resistant variant of human deoxyribonuclease I in CHO cells. Biotechnol Prog 2017;33:523-33. [PMID: 28127892 DOI: 10.1002/btpr.2439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
64 Liu Y, Liu Z, Wang K. The Ca2+-activated chloride channel ANO1/TMEM16A: An emerging therapeutic target for epithelium-originated diseases? Acta Pharm Sin B 2021;11:1412-33. [PMID: 34221860 DOI: 10.1016/j.apsb.2020.12.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Becker T, Pich A, Tamm S, Hedtfeld S, Ibrahim M, Altmüller J, Dalibor N, Toliat MR, Janciauskiene S, Tümmler B, Stanke F. Genetic information from discordant sibling pairs points to ESRP2 as a candidate trans-acting regulator of the CF modifier gene SCNN1B. Sci Rep 2020;10:22447. [PMID: 33384439 DOI: 10.1038/s41598-020-79804-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Perrem L, Stanojevic S, Solomon M, Carpenter S, Ratjen F. Incidence and risk factors of paediatric cystic fibrosis-related diabetes. J Cyst Fibros 2019;18:874-8. [PMID: 31072797 DOI: 10.1016/j.jcf.2019.04.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
67 Sagel SD, Khan U, Heltshe SL, Clancy JP, Borowitz D, Gelfond D, Donaldson SH, Moran A, Ratjen F, VanDalfsen JM, Rowe SM. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial. Ann Am Thorac Soc 2021;18:75-83. [PMID: 32644818 DOI: 10.1513/AnnalsATS.202002-144OC] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
68 Zhang L, Guo W, Lu Y. Advances in Cell‐Free Biosensors: Principle, Mechanism, and Applications. Biotechnol J 2020;15:2000187. [DOI: 10.1002/biot.202000187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
69 Kentgens A, Oppelaar M, Merkus P. A new breeze from an inspiring past: normality with multiple breath washout in school-aged children. Eur Respir J 2020;55:2000485. [DOI: 10.1183/13993003.00485-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Parodi A, Righetti G, Pesce E, Salis A, Tasso B, Urbinati C, Tomati V, Damonte G, Rusnati M, Pedemonte N, Cichero E, Millo E. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays. European Journal of Medicinal Chemistry 2020;208:112833. [DOI: 10.1016/j.ejmech.2020.112833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Mall MA, Mayer-Hamblett N, Rowe SM. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med 2020;201:1193-208. [PMID: 31860331 DOI: 10.1164/rccm.201910-1943SO] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
72 Fakıoğlu DM, Altun B. New Therapeutic Approaches in Cystic Fibrosis. Turk J Pharm Sci 2020;17:686-97. [PMID: 33389985 DOI: 10.4274/tjps.galenos.2020.76401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Gohy S, Moeremans A, Pilette C, Collin A. Immunoglobulin A Mucosal Immunity and Altered Respiratory Epithelium in Cystic Fibrosis. Cells 2021;10:3603. [PMID: 34944110 DOI: 10.3390/cells10123603] [Reference Citation Analysis]
74 Zainal Abidin N, Haq IJ, Gardner AI, Brodlie M. Ataluren in cystic fibrosis: development, clinical studies and where are we now? Expert Opinion on Pharmacotherapy 2017;18:1363-71. [DOI: 10.1080/14656566.2017.1359255] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
75 Saez-flores E, Tonarely NA, Barker DH, Quittner AL. Examining the Stability of the Hospital Anxiety and Depression Scale Factor Structure in Adolescents and Young Adults With Cystic Fibrosis: A Confirmatory Factor Analysis. Journal of Pediatric Psychology 2018;43:625-35. [DOI: 10.1093/jpepsy/jsx155] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
76 Kasawara KT, Castellanos MM, Hanada M, Reid WD. Pathophysiology of Muscle in Pulmonary and Cardiovascular Conditions. Cardiopulm Phys Ther J 2019;30:5-14. [DOI: 10.1097/cpt.0000000000000096] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Peignier A, Parker D. Pseudomonas aeruginosa Can Degrade Interferon λ, Thereby Repressing the Antiviral Response of Bronchial Epithelial Cells. J Interferon Cytokine Res 2020;40:429-31. [PMID: 32672514 DOI: 10.1089/jir.2020.0057] [Reference Citation Analysis]
78 Fernandez-Petty CM, Hughes GW, Bowers HL, Watson JD, Rosen BH, Townsend SM, Santos C, Ridley CE, Chu KK, Birket SE, Li Y, Leung HM, Mazur M, Garcia BA, Evans TIA, Libby EF, Hathorne H, Hanes J, Tearney GJ, Clancy JP, Engelhardt JF, Swords WE, Thornton DJ, Wiesmann WP, Baker SM, Rowe SM. A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus. JCI Insight 2019;4:125954. [PMID: 30996141 DOI: 10.1172/jci.insight.125954] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
79 Carlier FM, de Fays C, Pilette C. Epithelial Barrier Dysfunction in Chronic Respiratory Diseases. Front Physiol 2021;12:691227. [PMID: 34248677 DOI: 10.3389/fphys.2021.691227] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Mazio C, Scognamiglio LS, De Cegli R, Galietta LJV, Bernardo DD, Casale C, Urciuolo F, Imparato G, Netti PA. Intrinsic Abnormalities of Cystic Fibrosis Airway Connective Tissue Revealed by an In Vitro 3D Stromal Model. Cells 2020;9:E1371. [PMID: 32492951 DOI: 10.3390/cells9061371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Parker MFL, Luu JM, Schulte B, Huynh TL, Stewart MN, Sriram R, Yu MA, Jivan S, Turnbaugh PJ, Flavell RR, Rosenberg OS, Ohliger MA, Wilson DM. Sensing Living Bacteria in Vivo Using d-Alanine-Derived 11C Radiotracers. ACS Cent Sci 2020;6:155-65. [PMID: 32123733 DOI: 10.1021/acscentsci.9b00743] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
82 Scholl D, Sigoillot M, Overtus M, Martinez RC, Martens C, Wang Y, Pardon E, Laeremans T, Garcia-Pino A, Steyaert J, Sheppard DN, Hendrix J, Govaerts C. A topological switch in CFTR modulates channel activity and sensitivity to unfolding. Nat Chem Biol 2021. [PMID: 34341587 DOI: 10.1038/s41589-021-00844-0] [Reference Citation Analysis]
83 Muraglia KA, Chorghade RS, Kim BR, Tang XX, Shah VS, Grillo AS, Daniels PN, Cioffi AG, Karp PH, Zhu L, Welsh MJ, Burke MD. Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia. Nature 2019;567:405-8. [PMID: 30867598 DOI: 10.1038/s41586-019-1018-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
84 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
85 Coleman WB, Tsongalis GJ. Understanding molecular pathogenesis: the biological basis of human disease and implications for improved treatment of human disease. Essential Concepts in Molecular Pathology. Elsevier; 2020. pp. 191-200. [DOI: 10.1016/b978-0-12-813257-9.00012-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Alaa AM, van der Schaar M. Prognostication and Risk Factors for Cystic Fibrosis via Automated Machine Learning. Sci Rep 2018;8:11242. [PMID: 30050169 DOI: 10.1038/s41598-018-29523-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
87 Tang Y, Yan Z, Engelhardt JF. Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease. Hum Gene Ther 2020;31:524-37. [PMID: 32138545 DOI: 10.1089/hum.2020.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
88 Thornton CS, Surette MG. Potential Contributions of Anaerobes in Cystic Fibrosis Airways. J Clin Microbiol 2021;59:e01813-19. [PMID: 33115848 DOI: 10.1128/JCM.01813-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Sepahzad A, Morris-Rosendahl DJ, Davies JC. Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine. Genes (Basel) 2021;12:562. [PMID: 33924524 DOI: 10.3390/genes12040562] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Shei RJ, Peabody JE, Rowe SM. Functional Anatomic Imaging of the Airway Surface. Ann Am Thorac Soc 2018;15:S177-83. [PMID: 30431349 DOI: 10.1513/AnnalsATS.201806-407AW] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
91 Esposito A, D'Alonzo D, Fenza M, Gregorio E, Tamanini A, Lippi G, Dechecchi MC, Guaragna A. Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis. Int J Mol Sci 2020;21:E3353. [PMID: 32397443 DOI: 10.3390/ijms21093353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
92 Sommerburg O, Hämmerling S, Schneider SP, Okun J, Langhans CD, Leutz-Schmidt P, Wielpütz MO, Siems W, Gräber SY, Mall MA, Stahl M. CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. Antioxidants (Basel) 2021;10:483. [PMID: 33808590 DOI: 10.3390/antiox10030483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Liew Z, Mallikarjuna S, Hasan A, Gould FK, Bunn S, Thomas MF, Lordan JL, O'Brien C, Brodlie M. Successful outcome following pneumonectomy in a teenage boy with cystic fibrosis: a case report. BMC Pulm Med 2017;17:17. [PMID: 28086849 DOI: 10.1186/s12890-016-0350-x] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
94 Lee JA, Cho A, Huang EN, Xu Y, Quach H, Hu J, Wong AP. Gene therapy for cystic fibrosis: new tools for precision medicine. J Transl Med 2021;19:452. [PMID: 34717671 DOI: 10.1186/s12967-021-03099-4] [Reference Citation Analysis]
95 Hall JR, Maloney SE, Jin H, Taylor JB, Schoenfisch MH. Nitric oxide diffusion through cystic fibrosis-relevant media and lung tissue. RSC Adv 2019;9:40176-83. [PMID: 32655858 DOI: 10.1039/c9ra07367a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Hawkins FJ, Kotton DN. Pulmonary Ionocytes Challenge the Paradigm in Cystic Fibrosis. Trends in Pharmacological Sciences 2018;39:852-4. [DOI: 10.1016/j.tips.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
97 Schönenberger KA, Reber E, Bally L, Geiser T, Lin D, Stanga Z. Nutritional assessment in adults with cystic fibrosis. Nutrition 2019;67-68:110518. [PMID: 31473521 DOI: 10.1016/j.nut.2019.05.010] [Reference Citation Analysis]
98 Wang Y, Cai Z, Gosling M, Sheppard DN. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl channel by ivacaftor is temperature independent. American Journal of Physiology-Lung Cellular and Molecular Physiology 2018;315:L846-57. [DOI: 10.1152/ajplung.00235.2018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
99 Buroni S, Makarov V, Scoffone VC, Trespidi G, Riccardi G, Chiarelli LR. The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens. Eur J Med Chem 2020;190:112132. [PMID: 32066012 DOI: 10.1016/j.ejmech.2020.112132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
100 Schucht S, Minso R, Lex C, Reiss J, Stanke F, Tamm S, van Barneveld A, Tümmler B. Functional analysis of the p.[Arg74Trp;Val201Met;Asp1270Asn]/p.Phe508del CFTR mutation genotype in human native colon. Mol Genet Genomic Med 2019;7:e00526. [PMID: 30600599 DOI: 10.1002/mgg3.526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
101 Berical A, Lee RE, Randell SH, Hawkins F. Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis. Front Pharmacol 2019;10:74. [PMID: 30800069 DOI: 10.3389/fphar.2019.00074] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
102 Ratjen F, Waters V, Klingel M, McDonald N, Dell S, Leahy TR, Yau Y, Grasemann H. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 2016;47:829-36. [PMID: 26585432 DOI: 10.1183/13993003.01390-2015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
103 Greipel L, Fischer S, Klockgether J, Dorda M, Mielke S, Wiehlmann L, Cramer N, Tümmler B. Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients. Antimicrob Agents Chemother 2016;60:6726-34. [PMID: 27572404 DOI: 10.1128/AAC.00724-16] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
104 Nickolaus P, Jung B, Sabater J, Constant S, Gupta A. Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis. ERJ Open Res 2020;6:00429-2020. [PMID: 33313305 DOI: 10.1183/23120541.00429-2020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
105 Danahay H, Gosling M. TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis? Int J Mol Sci 2020;21:E2386. [PMID: 32235608 DOI: 10.3390/ijms21072386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
106 Loeven NA, Perault AI, Cotter PA, Hodges CA, Schwartzman JD, Hampton TH, Bliska JB. The Burkholderia cenocepacia Type VI Secretion System Effector TecA Is a Virulence Factor in Mouse Models of Lung Infection. mBio 2021;12:e0209821. [PMID: 34579569 DOI: 10.1128/mBio.02098-21] [Reference Citation Analysis]
107 Huang EN, Quach H, Lee JA, Dierolf J, Moraes TJ, Wong AP. A Developmental Role of the Cystic Fibrosis Transmembrane Conductance Regulator in Cystic Fibrosis Lung Disease Pathogenesis. Front Cell Dev Biol 2021;9:742891. [PMID: 34708042 DOI: 10.3389/fcell.2021.742891] [Reference Citation Analysis]
108 Mejías JC, Nelson MR, Liseth O, Roy K. A 96-well format microvascularized human lung-on-a-chip platform for microphysiological modeling of fibrotic diseases. Lab Chip 2020;20:3601-11. [PMID: 32990704 DOI: 10.1039/d0lc00644k] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
109 Perrem L, Ratjen F. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators. Pediatr Pulmonol 2019;54 Suppl 3:S46-55. [PMID: 31715088 DOI: 10.1002/ppul.24364] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
110 Hart SL, Harrison PT. Genetic therapies for cystic fibrosis lung disease. Curr Opin Pharmacol 2017;34:119-24. [PMID: 29107808 DOI: 10.1016/j.coph.2017.10.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
111 Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med 2021;203:585-93. [PMID: 33023304 DOI: 10.1164/rccm.202008-3177OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
112 Collin AM, Lecocq M, Noel S, Detry B, Carlier FM, Aboubakar Nana F, Bouzin C, Leal T, Vermeersch M, De Rose V, Regard L, Martin C, Burgel PR, Hoton D, Verleden S, Froidure A, Pilette C, Gohy S. Lung immunoglobulin A immunity dysregulation in cystic fibrosis. EBioMedicine 2020;60:102974. [PMID: 32927272 DOI: 10.1016/j.ebiom.2020.102974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
113 Fainardi V, Longo F, Chetta A, Esposito S, Pisi G. Sars-CoV-2 infection in patients with cystic fibrosis. An overview. Acta Biomed 2020;91:e2020035. [PMID: 32921729 DOI: 10.23750/abm.v91i3.10391] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
114 Somayaji R, Ramos KJ, Kapnadak SG, Aitken ML, Goss CH. Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency). Presse Med 2017;46:e109-24. [PMID: 28554722 DOI: 10.1016/j.lpm.2017.03.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
115 Zeren M, Cakir E, Gurses HN. Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: A randomised controlled trial. Respiratory Medicine 2019;148:24-30. [DOI: 10.1016/j.rmed.2019.01.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
116 Zardini Buzatto A, Abdel Jabar M, Nizami I, Dasouki M, Li L, Abdel Rahman AM. Lipidome Alterations Induced by Cystic Fibrosis, CFTR Mutation, and Lung Function. J Proteome Res 2021;20:549-64. [PMID: 33089695 DOI: 10.1021/acs.jproteome.0c00556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
117 Hughes DA, Archangelidi O, Coates M, Armstrong-James D, Elborn SJ, Carr SB, Davies JC. Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study. J Cyst Fibros 2021:S1569-1993(21)00117-X. [PMID: 33958279 DOI: 10.1016/j.jcf.2021.04.007] [Reference Citation Analysis]
118 Sasaki S, Sun R, Bui HH, Crosby JR, Monia BP, Guo S. Steric Inhibition of 5' UTR Regulatory Elements Results in Upregulation of Human CFTR. Mol Ther 2019;27:1749-57. [PMID: 31351782 DOI: 10.1016/j.ymthe.2019.06.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
119 Benden C, Schwarz C. CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis. Pulm Ther 2021;7:377-93. [PMID: 34406641 DOI: 10.1007/s41030-021-00170-9] [Reference Citation Analysis]
120 Li F, Egea PF, Vecchio AJ, Asial I, Gupta M, Paulino J, Bajaj R, Dickinson MS, Ferguson-Miller S, Monk BC, Stroud RM. Highlighting membrane protein structure and function: A celebration of the Protein Data Bank. J Biol Chem 2021;296:100557. [PMID: 33744283 DOI: 10.1016/j.jbc.2021.100557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
121 Sun X, Yi Y, Yan Z, Rosen BH, Liang B, Winter MC, Evans TIA, Rotti PG, Yang Y, Gray JS, Park SY, Zhou W, Zhang Y, Moll SR, Woody L, Tran DM, Jiang L, Vonk AM, Beekman JM, Negulescu P, Van Goor F, Fiorino DF, Gibson-Corley KN, Engelhardt JF. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med 2019;11:eaau7531. [PMID: 30918114 DOI: 10.1126/scitranslmed.aau7531] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 27.0] [Reference Citation Analysis]
122 Chin M, Tullis DE. Cystic Fibrosis in Pregnancy. In: Lapinsky SE, Plante LA, editors. Respiratory Disease in Pregnancy. Cambridge University Press; 2020. pp. 73-81. [DOI: 10.1017/9781108163705.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Shei RJ, Peabody JE, Kaza N, Rowe SM. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 2018;43:152-65. [PMID: 30340955 DOI: 10.1016/j.coph.2018.09.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
124 Bell GD, Yang Y, Leung E, Krissansen GW. mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446. PLoS One 2018;13:e0201464. [PMID: 30059522 DOI: 10.1371/journal.pone.0201464] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
125 Ibarra-gonzález I, Campos-garcia F, Herrera-pérez LDA, Martínez-cruz P, Moreno-graciano C, Contreras-capetillo S, León-burgos V, Maldonado-solis F, Alcántara-ortigoza MA, González del Angel A, Vela-amieva M. Newborn cystic fibrosis screening in southeastern Mexico: Birth prevalence and novel CFTR gene variants. J Med Screen 2018;25:119-25. [DOI: 10.1177/0969141317722808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
126 Raraigh KS, Aksit MA, Hetrick K, Pace RG, Ling H, O'Neal W, Blue E, Zhou YH, Bamshad MJ, Blackman SM, Gibson RL, Knowles MR, Cutting GR. Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment. J Cyst Fibros 2021:S1569-1993(21)02113-5. [PMID: 34782259 DOI: 10.1016/j.jcf.2021.10.011] [Reference Citation Analysis]
127 Favia M, Gallo C, Guerra L, De Venuto D, Diana A, Polizzi AM, Montemurro P, Mariggiò MA, Leonetti G, Manca A, Casavola V, Conese M. Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi®) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells. Int J Mol Sci 2020;21:E2398. [PMID: 32244302 DOI: 10.3390/ijms21072398] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
128 Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med 2021;203:1522-32. [PMID: 33734030 DOI: 10.1164/rccm.202102-0509OC] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
129 Li H, Valkenier H, Thorne AG, Dias CM, Cooper JA, Kieffer M, Busschaert N, Gale PA, Sheppard DN, Davis AP. Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs. Chem Sci 2019;10:9663-72. [PMID: 32055336 DOI: 10.1039/c9sc04242c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 9.3] [Reference Citation Analysis]
130 Danahay HL, Lilley S, Fox R, Charlton H, Sabater J, Button B, McCarthy C, Collingwood SP, Gosling M. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis. Am J Respir Crit Care Med 2020;201:946-54. [PMID: 31898911 DOI: 10.1164/rccm.201908-1641OC] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
131 Gonska T, Ratjen F. Newborn screening for cystic fibrosis. Expert Review of Respiratory Medicine 2015;9:619-31. [DOI: 10.1586/17476348.2015.1085804] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
132 Hennemann LC, LaFayette SL, Malet JK, Bortolotti P, Yang T, McKay GA, Houle D, Radzioch D, Rousseau S, Nguyen D. LasR-deficient Pseudomonas aeruginosa variants increase airway epithelial mICAM-1 expression and enhance neutrophilic lung inflammation. PLoS Pathog 2021;17:e1009375. [PMID: 33690714 DOI: 10.1371/journal.ppat.1009375] [Reference Citation Analysis]
133 Duchesneau P, Waddell TK, Karoubi G. Cell-Based Therapeutic Approaches for Cystic Fibrosis. Int J Mol Sci 2020;21:E5219. [PMID: 32718005 DOI: 10.3390/ijms21155219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
134 Awatade NT, Wong SL, Hewson CK, Fawcett LK, Kicic A, Jaffe A, Waters SA. Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine. Front Pharmacol 2018;9:1429. [PMID: 30581387 DOI: 10.3389/fphar.2018.01429] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
135 Lima EDS, Pezzin LS, Fensterseifer AC, Pinto LA. Frequency of CFTR variants in southern Brazil and indication for modulators therapy in patients with cystic fibrosis. Genet Mol Biol 2021;45:e20200275. [PMID: 34874053 DOI: 10.1590/1678-4685-GMB-2020-0275] [Reference Citation Analysis]
136 Moran Losada P, Chouvarine P, Dorda M, Hedtfeld S, Mielke S, Schulz A, Wiehlmann L, Tümmler B. The cystic fibrosis lower airways microbial metagenome. ERJ Open Res 2016;2:00096-2015. [PMID: 27730195 DOI: 10.1183/23120541.00096-2015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
137 Ademhan Tural D, Emiralioglu N, Tural Hesapcioglu S, Karahan S, Ozsezen B, Sunman B, Nayir Buyuksahin H, Yalcin E, Dogru D, Ozcelik U, Kiper N. Psychiatric and general health effects of COVID-19 pandemic on children with chronic lung disease and parents' coping styles. Pediatr Pulmonol 2020;55:3579-86. [PMID: 32946202 DOI: 10.1002/ppul.25082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
138 Bocharova YA, Savinova TA, Lyamin AV, Kondratenko OV, Polikarpova SV, Zhilina SV, Fedorova NI, Semykin SY, Chaplin AV, Korostin DO, Mayansky NA, Chebotar IV. Genome features and antibiotic resistance of Pseudomonas aeruginosa strains isolated in patients with cystic fibrosis in the Russian Federation. Klin Lab Diagn 2021;66:629-34. [PMID: 34665950 DOI: 10.51620/0869-2084-2021-66-10-629-634] [Reference Citation Analysis]
139 Stanke F, Tümmler B. Classification of CFTR mutation classes. Lancet Respir Med 2016;4:e36. [PMID: 27377412 DOI: 10.1016/S2213-2600(16)30147-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
140 Zhou Z, Alvarez D, Milla C, Zare RN. Proof of concept for identifying cystic fibrosis from perspiration samples. Proc Natl Acad Sci U S A 2019;116:24408-12. [PMID: 31740593 DOI: 10.1073/pnas.1909630116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
141 Graham C, Hart S. CRISPR/Cas9 gene editing therapies for cystic fibrosis. Expert Opin Biol Ther 2021;21:767-80. [PMID: 33412935 DOI: 10.1080/14712598.2021.1869208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Fischer S, Stanke F, Tümmler B. VJ Segment Usage of TCR-Beta Repertoire in Monozygotic Cystic Fibrosis Twins. Front Immunol 2021;12:599133. [PMID: 33708199 DOI: 10.3389/fimmu.2021.599133] [Reference Citation Analysis]
143 Knudsen KB, Pressler T, Mortensen LH, Jarden M, Skov M, Quittner AL, Katzenstein T, Boisen KA. Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis. Springerplus. 2016;5:1216. [PMID: 27516954 DOI: 10.1186/s40064-016-2862-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
144 Ratnayake I, Ahern S, Ruseckaite R. Patient-Reported Outcome Measures in Cystic Fibrosis: Protocol for a Systematic Review. JMIR Res Protoc 2020;9:e15467. [PMID: 32374269 DOI: 10.2196/15467] [Reference Citation Analysis]
145 Shrestha J, Razavi Bazaz S, Aboulkheyr Es H, Yaghobian Azari D, Thierry B, Ebrahimi Warkiani M, Ghadiri M. Lung-on-a-chip: the future of respiratory disease models and pharmacological studies. Crit Rev Biotechnol 2020;40:213-30. [PMID: 31906727 DOI: 10.1080/07388551.2019.1710458] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
146 Wen KY, Cameron L, Chappell J, Jensen K, Bell DJ, Kelwick R, Kopniczky M, Davies JC, Filloux A, Freemont PS. A Cell-Free Biosensor for Detecting Quorum Sensing Molecules in P. aeruginosa-Infected Respiratory Samples. ACS Synth Biol 2017;6:2293-301. [PMID: 28981256 DOI: 10.1021/acssynbio.7b00219] [Cited by in Crossref: 77] [Cited by in F6Publishing: 53] [Article Influence: 15.4] [Reference Citation Analysis]
147 Koeppen K, Barnaby R, Jackson AA, Gerber SA, Hogan DA, Stanton BA. Tobramycin reduces key virulence determinants in the proteome of Pseudomonas aeruginosa outer membrane vesicles. PLoS One 2019;14:e0211290. [PMID: 30682135 DOI: 10.1371/journal.pone.0211290] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
148 Qiu F, Habgood M, Schneider-Futschik EK. The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. ACS Pharmacol Transl Sci 2020;3:835-43. [PMID: 33073185 DOI: 10.1021/acsptsci.0c00098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
149 Roy A, Talukdar P. Recent Advances in Bioactive Artificial Ionophores. Chembiochem 2021. [PMID: 34043277 DOI: 10.1002/cbic.202100112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
150 Parekh KR, Nawroth J, Pai A, Busch SM, Senger CN, Ryan AL. Stem cells and lung regeneration. Am J Physiol Cell Physiol 2020;319:C675-93. [PMID: 32783658 DOI: 10.1152/ajpcell.00036.2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
151 Weiner GA, Forno E, Weiner DJ. The effects of high‐frequency chest compression on end‐tidal CO 2. Pediatric Pulmonology 2020;55:646-8. [DOI: 10.1002/ppul.24588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
152 Valk A, Willers C, Shahim K, Pusterla O, Bauman G, Sandkühler R, Bieri O, Wyler F, Latzin P. Defect distribution index: A novel metric for functional lung MRI in cystic fibrosis. Magn Reson Med 2021. [PMID: 34337778 DOI: 10.1002/mrm.28947] [Reference Citation Analysis]
153 Gaul R, Ramsey JM, Heise A, Cryan S, Greene CM. Nanotechnology approaches to pulmonary drug delivery. Design of Nanostructures for Versatile Therapeutic Applications. Elsevier; 2018. pp. 221-53. [DOI: 10.1016/b978-0-12-813667-6.00006-1] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
154 da Silva Filho LVRF, Maróstica PJC, Athanazio RA, Reis FJC, Damaceno N, Paes AT, Hira AY, Schlesinger D, Kok F, Amaral MD; Brazilian Cystic Fibrosis Patient Registry Contributors Team. Extensive CFTR sequencing through NGS in Brazilian individuals with cystic fibrosis: unravelling regional discrepancies in the country. J Cyst Fibros 2021;20:473-84. [PMID: 32819855 DOI: 10.1016/j.jcf.2020.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Meng X, Wang Y, Wang X, Wrennall JA, Rimington TL, Li H, Cai Z, Ford RC, Sheppard DN. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. J Biol Chem 2017;292:3706-19. [PMID: 28087700 DOI: 10.1074/jbc.M116.751537] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 6.6] [Reference Citation Analysis]
156 Rosenfeld M, Faino AV, Onchiri F, Aksit MA, Blackman SM, Blue EE, Collaco JM, Gordon WW, Pace RG, Raraigh KS, Zhou YH, Cutting GR, Knowles MR, Bamshad MJ, Gibson RL. Comparing encounter-based and annualized chronic pseudomonas infection definitions in cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)01339-4. [PMID: 34393091 DOI: 10.1016/j.jcf.2021.07.020] [Reference Citation Analysis]
157 O'Toole DPH, Latchford GJ, Duff AJA, Ball R, McCormack P, McNamara PS, Brownlee KG, Southern KW. Adherence to Aerosol Therapy in Young People With Cystic Fibrosis: Patient and Parent Perspectives Following Electronic Data Capture. Qual Health Res 2019;29:846-56. [PMID: 30371143 DOI: 10.1177/1049732318805754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Hanrahan JW, Sato Y, Carlile GW, Jansen G, Young JC, Thomas DY. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets. Expert Opin Ther Targets 2019;23:711-24. [PMID: 31169041 DOI: 10.1080/14728222.2019.1628948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
159 Wojtaszczyk A, Glajchen M, Portenoy RK, Berdella M, Walker P, Barrett M, Chen J, Plachta A, Balzano J, Fresenius A, Wilder K, Langfelder-Schwind E, Dhingra L. Trajectories of caregiver burden in families of adult cystic fibrosis patients. Palliat Support Care 2018;16:732-40. [PMID: 29037271 DOI: 10.1017/S1478951517000918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
160 van der Schoor L, van Hattum EJ, de Wilde SM, Harlianto NI, van Weert AJ, Bloothooft M, van der Heyden MAG. Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease. Int J Mol Sci 2020;21:E5746. [PMID: 32796537 DOI: 10.3390/ijms21165746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Thorat T, McGarry LJ, Jariwala-Parikh K, Limone B, Bonafede M, Chandarana K, Konstan MW. Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulm Ther 2021;7:281-93. [PMID: 33913076 DOI: 10.1007/s41030-021-00154-9] [Reference Citation Analysis]
162 Phuan PW, Veit G, Tan JA, Roldan A, Finkbeiner WE, Haggie PM, Lukacs GL, Verkman AS. ΔF508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter. SLAS Discov 2018;23:823-31. [PMID: 29533733 DOI: 10.1177/2472555218763310] [Reference Citation Analysis]
163 Sato Y, Mustafina KR, Luo Y, Martini C, Thomas DY, Wiseman PW, Hanrahan JW. Nonspecific binding of common anti-CFTR antibodies in ciliated cells of human airway epithelium. Sci Rep 2021;11:23256. [PMID: 34853321 DOI: 10.1038/s41598-021-02420-x] [Reference Citation Analysis]
164 Ratnayake I, Ahern S, Ruseckaite R. Acceptability of patient reported outcome measures (PROMs) in a cystic fibrosis data registry. BMJ Open Respir Res 2021;8:e000927. [PMID: 34281916 DOI: 10.1136/bmjresp-2021-000927] [Reference Citation Analysis]
165 Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 2019;5:00082-2019. [PMID: 31218221 DOI: 10.1183/23120541.00082-2019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
166 Durmowicz AG, Lim R, Rogers H, Rosebraugh CJ, Chowdhury BA. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial. Annals ATS 2018;15:1-2. [DOI: 10.1513/annalsats.201708-668ps] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 13.5] [Reference Citation Analysis]
167 Abu-Arish A, Pandžić E, Kim D, Tseng HW, Wiseman PW, Hanrahan JW. Agonists that stimulate secretion promote the recruitment of CFTR into membrane lipid microdomains. J Gen Physiol 2019;151:834-49. [PMID: 31048413 DOI: 10.1085/jgp.201812143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
168 Yadav R, Yoo DG, Kahlenberg JM, Bridges SL Jr, Oni O, Huang H, Stecenko A, Rada B. Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis. J Cyst Fibros 2019;18:636-45. [PMID: 30638826 DOI: 10.1016/j.jcf.2018.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
169 Cao H, Ouyang H, Laselva O, Bartlett C, Zhou ZP, Duan C, Gunawardena T, Avolio J, Bear CE, Gonska T, Hu J, Moraes TJ. A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations. Eur Respir J 2020;56:2000205. [PMID: 32457197 DOI: 10.1183/13993003.00205-2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
170 Hanrahan JW, Matthes E, Carlile G, Thomas DY. Corrector combination therapies for F508del-CFTR. Curr Opin Pharmacol 2017;34:105-11. [PMID: 29080476 DOI: 10.1016/j.coph.2017.09.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
171 Yang B, Lei C, Yang D, Tan Z, Guo T, Luo H. Whole-Exome Sequencing Identified CFTR Variants in Two Consanguineous Families in China. Front Genet 2021;12:631221. [PMID: 34276759 DOI: 10.3389/fgene.2021.631221] [Reference Citation Analysis]
172 Middour-Oxler B, Bergman S, Blair S, Pendley S, Stecenko A, Hunt WR. Formal vs. informal transition in adolescents with cystic fibrosis: A retrospective comparison of outcomes. J Pediatr Nurs 2021:S0882-5963(21)00175-5. [PMID: 34172371 DOI: 10.1016/j.pedn.2021.06.004] [Reference Citation Analysis]
173 Bell SC, Armstrong D, Harrington G, Jardine L, Divakaran R, Loff B, Middleton PG, McDonald T, Rowland K, Wishart M, Wood ME, Stuart RL. Work environment risks for health care workers with cystic fibrosis. Respirology 2018;23:1190-7. [PMID: 30215873 DOI: 10.1111/resp.13404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Linnemann RW, Yadav R, Zhang C, Sarr D, Rada B, Stecenko AA. Serum anti-PAD4 autoantibodies are present in cystic fibrosis children and increase with age and lung disease severity. Autoimmunity. [DOI: 10.1080/08916934.2021.2021193] [Reference Citation Analysis]
175 Chorghade RS, Kim BR, Launspach JL, Karp PH, Welsh MJ, Burke MD. Amphotericin B induces epithelial voltage responses in people with cystic fibrosis. J Cyst Fibros 2021;20:540-50. [PMID: 33309058 DOI: 10.1016/j.jcf.2020.11.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
176 Kaeslin J, Micic S, Weber R, Müller S, Perkins N, Berger C, Zenobi R, Bruderer T, Moeller A. Differentiation of Cystic Fibrosis-Related Pathogens by Volatile Organic Compound Analysis with Secondary Electrospray Ionization Mass Spectrometry. Metabolites 2021;11:773. [PMID: 34822431 DOI: 10.3390/metabo11110773] [Reference Citation Analysis]
177 Leung HM, Birket SE, Hyun C, Ford TN, Cui D, Solomon GM, Shei RJ, Adewale AT, Lenzie AR, Fernandez-Petty CM, Zheng H, Palermo JH, Cho DY, Woodworth BA, Yonker LM, Hurley BP, Rowe SM, Tearney GJ. Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies. Sci Transl Med 2019;11:eaav3505. [PMID: 31391319 DOI: 10.1126/scitranslmed.aav3505] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
178 Ratjen F. Pulmonary artery hypertension: an underrated disease manifestation in cystic fibrosis? Lancet Respir Med 2016;4:596-8. [PMID: 27298018 DOI: 10.1016/S2213-2600(16)30107-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Baldassi D, Gabold B, Merkel O. Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions. Adv Nanobiomed Res 2021;1:2000111. [PMID: 34345878 DOI: 10.1002/anbr.202000111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Shei RJ, Mackintosh KA, Peabody Lever JE, McNarry MA, Krick S. Exercise Physiology Across the Lifespan in Cystic Fibrosis. Front Physiol 2019;10:1382. [PMID: 31780953 DOI: 10.3389/fphys.2019.01382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Dumas MP, Xia S, Bear CE, Ratjen F. Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis. EBioMedicine 2021;73:103660. [PMID: 34740114 DOI: 10.1016/j.ebiom.2021.103660] [Reference Citation Analysis]
182 Sala V, Cnudde SJ, Murabito A, Massarotti A, Hirsch E, Ghigo A. Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives. Eur J Med Chem 2021;213:113191. [PMID: 33493828 DOI: 10.1016/j.ejmech.2021.113191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Mantoo MR, Kabra M, Kabra SK. Cystic Fibrosis Presenting as Pseudo-Bartter Syndrome: An Important Diagnosis that is Missed! Indian J Pediatr 2020;87:726-32. [DOI: 10.1007/s12098-020-03342-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
184 Chusilp S, Li B, Lee D, Lee C, Vejchapipat P, Pierro A. Intestinal organoids in infants and children. Pediatr Surg Int 2020;36:1-10. [PMID: 31555860 DOI: 10.1007/s00383-019-04581-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
185 Xu J, Livraghi-Butrico A, Hou X, Rajagopalan C, Zhang J, Song J, Jiang H, Wei HG, Wang H, Bouhamdan M, Ruan J, Yang D, Qiu Y, Xie Y, Barrett R, McClellan S, Mou H, Wu Q, Chen X, Rogers TD, Wilkinson KJ, Gilmore RC, Esther CR Jr, Zaman K, Liang X, Sobolic M, Hazlett L, Zhang K, Frizzell RA, Gentzsch M, O'Neal WK, Grubb BR, Chen YE, Boucher RC, Sun F. Phenotypes of CF rabbits generated by CRISPR/Cas9-mediated disruption of the CFTR gene. JCI Insight 2021;6:139813. [PMID: 33232302 DOI: 10.1172/jci.insight.139813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
186 Mędza A, Kaźmierska K, Wielgomas B, Konieczna L, Olędzka I, Szlagatys-Sidorkiewicz A, Sznurkowska K. DeltaF508 CFTR Hetero- and Homozygous Paediatric Patients with Cystic Fibrosis Do Not Differ with Regard to Nutritional Status. Nutrients 2021;13:1402. [PMID: 33919435 DOI: 10.3390/nu13051402] [Reference Citation Analysis]
187 Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, Sanders DB, Davis SD, Ratjen F. Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. Am J Respir Crit Care Med 2021;203:977-86. [PMID: 33030967 DOI: 10.1164/rccm.202006-2433OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
188 Hammoudeh S, Gadelhak W, AbdulWahab A, Al-Langawi M, Janahi IA. Approaching two decades of cystic fibrosis research in Qatar: a historical perspective and future directions. Multidiscip Respir Med 2019;14:29. [PMID: 31583102 DOI: 10.1186/s40248-019-0193-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Stanton BA. Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response. Am J Physiol Cell Physiol 2017;312:C357-66. [PMID: 28122735 DOI: 10.1152/ajpcell.00373.2016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
190 Healy C, Munoz-Wolf N, Strydom J, Faherty L, Williams NC, Kenny S, Donnelly SC, Cloonan SM. Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease. Respir Res 2021;22:133. [PMID: 33926483 DOI: 10.1186/s12931-021-01722-y] [Reference Citation Analysis]
191 Sheppard DN, Davis AP. Pore-forming small molecules offer a promising way to tackle cystic fibrosis. Nature 2019;567:315-7. [DOI: 10.1038/d41586-019-00781-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
192 Koumangoye R, Bastarache L, Delpire E. NKCC1: Newly Found as a Human Disease-Causing Ion Transporter. Function (Oxf) 2021;2:zqaa028. [PMID: 33345190 DOI: 10.1093/function/zqaa028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
193 Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H, Dekkers JF, Kumawat K, Ramos E, van Oosterhout MF, Offerhaus GJ, Wiener DJ, Olimpio EP, Dijkstra KK, Smit EF, van der Linden M, Jaksani S, van de Ven M, Jonkers J, Rios AC, Voest EE, van Moorsel CH, van der Ent CK, Cuppen E, van Oudenaarden A, Coenjaerts FE, Meyaard L, Bont LJ, Peters PJ, Tans SJ, van Zon JS, Boj SF, Vries RG, Beekman JM, Clevers H. Long-term expanding human airway organoids for disease modeling. EMBO J 2019;38:e100300. [PMID: 30643021 DOI: 10.15252/embj.2018100300] [Cited by in Crossref: 213] [Cited by in F6Publishing: 213] [Article Influence: 71.0] [Reference Citation Analysis]
194 Frisch S, Boese A, Huck B, Horstmann JC, Ho DK, Schwarzkopf K, Murgia X, Loretz B, de Souza Carvalho-Wodarz C, Lehr CM. A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms. J Antimicrob Chemother 2021;76:1472-9. [PMID: 33712824 DOI: 10.1093/jac/dkab068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Kaireit TF, Sorrentino SA, Renne J, Schoenfeld C, Voskrebenzev A, Gutberlet M, Schulz A, Jakob PM, Hansen G, Wacker F, Welte T, Tümmler B, Vogel-Claussen J. Functional lung MRI for regional monitoring of patients with cystic fibrosis. PLoS One 2017;12:e0187483. [PMID: 29216201 DOI: 10.1371/journal.pone.0187483] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
196 De Palma FDE, Raia V, Kroemer G, Maiuri MC. The Multifaceted Roles of MicroRNAs in Cystic Fibrosis. Diagnostics (Basel) 2020;10:E1102. [PMID: 33348555 DOI: 10.3390/diagnostics10121102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Ferrera L, Cappiello F, Loffredo MR, Puglisi E, Casciaro B, Botta B, Galietta LJV, Mori M, Mangoni ML. Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides. Cell Mol Life Sci 2021. [PMID: 34971429 DOI: 10.1007/s00018-021-04030-2] [Reference Citation Analysis]
198 Santo AH, Silva-Filho LVRFD. Cystic fibrosis-related mortality trends in Brazil for the 1999-2017 period: a multiple-cause-of-death study. J Bras Pneumol 2021;47:e20200166. [PMID: 33656158 DOI: 10.36416/1806-3756/e20200166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Declercq M, de Zeeuw P, Conchinha NV, Geldhof V, Ramalho AS, García-Caballero M, Brepoels K, Ensinck M, Carlon MS, Bird MJ, Vinckier S, Proesmans M, Vermeulen F, Dupont L, Ghesquière B, Dewerchin M, Carmeliet P, Cassiman D, Treps L, Eelen G, Witters P. Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype. Eur Respir J 2021;57:2000261. [PMID: 33184117 DOI: 10.1183/13993003.00261-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
200 Harwood KH, McQuade RM, Jarnicki A, Schneider-Futschik EK. Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis. Int J Mol Sci 2021;22:7606. [PMID: 34299226 DOI: 10.3390/ijms22147606] [Reference Citation Analysis]
201 Ratnayake I, Ahern S, Ruseckaite R. A systematic review of patient-reported outcome measures (PROMs) in cystic fibrosis. BMJ Open 2020;10:e033867. [PMID: 33004381 DOI: 10.1136/bmjopen-2019-033867] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
202 Nicolais CJ, Bernstein R, Saez-flores E, Mclean KA, Riekert KA, Quittner AL. Identifying Factors that Facilitate Treatment Adherence in Cystic Fibrosis: Qualitative Analyses of Interviews with Parents and Adolescents. J Clin Psychol Med Settings 2019;26:530-40. [DOI: 10.1007/s10880-018-9598-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
203 Perniss A, Preiss K, Nier M, Althaus M. Hydrogen sulfide stimulates CFTR in Xenopus oocytes by activation of the cAMP/PKA signalling axis. Sci Rep 2017;7:3517. [PMID: 28615646 DOI: 10.1038/s41598-017-03742-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
204 Morejón García G, García de la Rosa I, Feal Carballo S, Castells Martínez EM, Stable Vernier IC, Quintana Guerra JM, Hernández Pérez L, Lafita Delfino Y, Pérez Morás PL, Pupo Infante M, Figueredo Lago JE, González Reyes EC. Generation and characterization of murine monoclonal antibodies against immunoreactive trypsinogen for newborn screening of cystic fibrosis. Anal Biochem 2020;591:113569. [PMID: 31887264 DOI: 10.1016/j.ab.2019.113569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, Avolio J, Esmaeili M, Zhang L, He G, Soave D, Mastromatteo S, Baskurt Z, Kim S, O'Neal WK, Polineni D, Blackman SM, Corvol H, Cutting GR, Drumm M, Knowles MR, Rommens JM, Sun L, Strug LJ. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. PLoS Genet 2019;15:e1008007. [PMID: 30807572 DOI: 10.1371/journal.pgen.1008007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
206 Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Am J Respir Crit Care Med 2018;197:1433-42. [PMID: 29327948 DOI: 10.1164/rccm.201710-1983OC] [Cited by in Crossref: 52] [Cited by in F6Publishing: 29] [Article Influence: 17.3] [Reference Citation Analysis]
207 Kallingal A, Thachan Kundil V, Ayyolath A, Muringayil Joseph T, Kar Mahapatra D, Haponiuk JT, Variyar EJ. Identification of sustainable trypsin active-site inhibitors from Nigrospora sphaerica strain AVA-1. J Basic Microbiol 2021;61:709-20. [PMID: 34228389 DOI: 10.1002/jobm.202100221] [Reference Citation Analysis]
208 Rang C, Keating D, Wilson J, Kotsimbos T. Re-imagining cystic fibrosis care: next generation thinking. Eur Respir J 2020;55:1902443. [PMID: 32139465 DOI: 10.1183/13993003.02443-2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
209 Pınar Senkalfa B, Sismanlar Eyuboglu T, Aslan AT, Ramaslı Gursoy T, Soysal AS, Yapar D, İlhan MN. Effect of the COVID-19 pandemic on anxiety among children with cystic fibrosis and their mothers. Pediatr Pulmonol 2020;55:2128-34. [PMID: 32530552 DOI: 10.1002/ppul.24900] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]